Catalog No.S1140 Synonyms: GTx-007, S-4

For research use only.

Andarine (GTx-007, S-4) is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs. Phase 3.

Andarine Chemical Structure

CAS No. 401900-40-1

Selleck's Andarine has been cited by 6 Publications

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Other Androgen Receptor Products

Biological Activity

Description Andarine (GTx-007, S-4) is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs. Phase 3.
Androgen Receptor [1]
4 nM(Ki)
In vitro

Andarine stimulates AR-mediated transcription to 93% of that observed for 1 nM DHT at a concentration of 10 nM. [1]

In vivo Andarine exhibits potent and efficacious anabolic activity and results in dose-dependent stimulation of growth in prostate, seminal vesicles, and levator ani muscle with the ED50 of 0.43 mg/day, 0.55 mg/day, and 0.14 mg/day, respectively. Besides, Andarine shows no dose-dependent effect on castration-induced change in FSH, and partially suppresses LH production at dose rates of 0.5 mg/day or higher. [1] In dogs administrated by intravenous doses of Andarine (0.1, 1, 3, and 10 mg/kg), the total body clearance (CL) ranged from 7.4 mL/min/kg to 3.1 mL/min/kg, volume of distribution at steady state (Vss) is 1.39 L/kg and half-life of Andarine is 229 minutes, respectively. In addition, oral bioavailability is 38%, 62% and 91% for the 10 mg/kg, 1 mg/kg and 0.1 mg/kg doses, respectively. [2] Andarine demonstrates tissue-selective pharmacological activity and significantly decreased prostate weight to 79.4% at a concentration of 0.5 mg/day in intact rats. [3]

Protocol (from reference)

Animal Research:[1]
  • Animal Models: Male Sprague-Dawley rats and castrated rat model.
  • Dosages: ≤1 mg/day
  • Administration: Administered via osmotic pump.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 441.36


CAS No. 401900-40-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)NC1=CC=C(C=C1)OCC(C)(C(=O)NC2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05409820 Not yet recruiting Procedure: use of different spinal anesthesia techniques Spinal Anesthesia Techniques Ankara City Hospital Bilkent June 15 2022 --
NCT04577599 Recruiting Other: Mobile Low-dose Computed Tomography (LDCT) Screening Lung Neoplasms|Lung Cancer Wake Forest University Health Sciences|Leon Levine Foundation January 6 2021 Not Applicable
NCT04572906 Recruiting Combination Product: NTX-001 Peripheral Nerve Injuries Neuraptive Therapeutics Inc. September 25 2020 Phase 2
NCT03938077 Withdrawn Device: Storytelling 4 Empowerment HIV/AIDS and Infections|Drug Abuse|Adolescent Behavior|Drug Usage|Alcohol Use|Mental Health|Tobacco Use|HIV Testing University of Michigan October 1 2019 Not Applicable
NCT04099173 Active not recruiting Behavioral: Brief Mindfulness Based Intervention Suicidal Ideation|Psychiatric Disorder|Addiction VA Salt Lake City Health Care System September 1 2019 Not Applicable

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Andarine | Andarine supplier | purchase Andarine | Andarine cost | Andarine manufacturer | order Andarine | Andarine distributor